Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market
Biogen found itself at the center of controversy late last year as it worked with the FDA to grease the wheels for its controversial Alzheimer’s med aducanumab. That back and forth led to accusations the agency wasn’t being impartial in its review — consider the question of whether the drug even works — but for Biogen CEO Michel Vounatsos, controversy proved lucrative.
Vounatsos bagged an $18.67 million pay package in 2020 as Biogen has pushed to get aducanumab over the finish line despite pushback from an FDA advisory committee and consumer advocates, according to an SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
